相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Detection of phospho-STAT5 in mast cells: a reliable phenotypic marker of systemic mast cell disease that reflects constitutive tyrosine kinase activation
Tania Zuluaga Toro et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Cytoplasmic localization of phosphorylated STAT5 in human acute myeloid leukemia is inversely correlated with Flt3-ITD
Kevin D. Bunting et al.
BLOOD (2007)
Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias
Noria Harir et al.
BLOOD (2007)
Standards and standardization in mastocytosis: Consensus statements on diagnostics, treatment recommendations and response criteria
P. Valent et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2007)
Stat5 expression is required for IgE-mediated mast cell function
Brian O. Barnstein et al.
JOURNAL OF IMMUNOLOGY (2006)
STAT5 signaling is required for the efficient induction and maintenance of CML in mice
Dan Ye et al.
BLOOD (2006)
Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation
Andrea Hoelbl et al.
BLOOD (2006)
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT:: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects
KV Gleixner et al.
BLOOD (2006)
Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation
JP Zappulla et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation
J Gotlib et al.
BLOOD (2005)
Activated STAT5 proteins induce activation of the PI 3-kinase/Akt and Ras/MAPK pathways via the Gab2 scaffolding adapter
R Nyga et al.
BIOCHEMICAL JOURNAL (2005)
Activation mutations of human c-KIT resistant to imatinib, mesylate are sensitive to the tyrosine kinase inhibitor PKC412
JD Growney et al.
BLOOD (2005)
Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis
Y Kato et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Rapid and large amount of autocrine IL-3 production is responsible for mast cell survival by IgE in the absence of antigen
M Kohno et al.
BLOOD (2005)
Mast cells in the development of adaptive immune responses
SJ Galli et al.
NATURE IMMUNOLOGY (2005)
Stat5 tetramer formation is associated with leukemogenesis
R Moriggl et al.
CANCER CELL (2005)
Constitutive activation of STAT5A promotes human hematopoietic stem cell self-renewal and erythroid differentiation
JJ Schuringa et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Systemic mastocytosis
C Akin et al.
ANNUAL REVIEW OF MEDICINE (2004)
Diagnosis and treatment of systemic mastocytosis: State of the art
P Valent et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Role of phosphoinositide 3-kinase signaling in mast cells: new insights from knockout mouse studies
T Fukao et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2003)
Stat5 expression is critical for mast cell development and survival
CP Shelburne et al.
BLOOD (2003)
Signal transducer and activator of transcription proteins in leukemias
M Benekli et al.
BLOOD (2003)
Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms
Y Zermati et al.
ONCOGENE (2003)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia
ME Gorre et al.
CURRENT OPINION IN HEMATOLOGY (2002)
Critical role for Gab2 in transformation by BCR/ABL
M Sattler et al.
CANCER CELL (2002)
Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5
KD Bunting et al.
BLOOD (2002)
Selective loss of gastrointestinal mast cells and impaired immunity in PI3K-deficient mice
T Fukao et al.
NATURE IMMUNOLOGY (2002)
The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations
YS Ma et al.
BLOOD (2002)
The TEL/PDGFβR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways
DW Sternberg et al.
BLOOD (2001)
Quantitative analysis of synthetic gene delivery vector design properties
CM Varga et al.
MOLECULAR THERAPY (2001)
Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant
RJ Chian et al.
BLOOD (2001)
TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3-kinase/protein kinase B signaling pathway
MHH Nguyen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
Diagnostic criteria and classification of mastocytosis:: a consensus proposal
P Valent et al.
LEUKEMIA RESEARCH (2001)
Mastocytosis: molecular mechanisms and clinical disease heterogeneity
DD Metcalfe et al.
LEUKEMIA RESEARCH (2001)
Mast cell lineage development and phenotypic regulation
KF Austen et al.
LEUKEMIA RESEARCH (2001)
Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis:: Evidence for expression of CD2, CD117/Kit, and bcl-xL
JH Jordan et al.
HUMAN PATHOLOGY (2001)
Kit signal transduction
ML Taylor et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2000)
Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2
J Schwaller et al.
MOLECULAR CELL (2000)
分享论文
